| Year |
Citation |
Score |
| 2022 |
Lucas LM, Dwivedi V, Senfeld JI, Cullum RL, Mill CP, Piazza JT, Bryant IN, Cook LJ, Miller ST, Lott JH, Kelley CM, Knerr EL, Markham JA, Kaufmann DP, Jacobi MA, et al. The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein. Pharmacological Reviews. 74: 18-47. PMID 34987087 DOI: 10.1124/pharmrev.121.000381 |
0.751 |
|
| 2020 |
Cullum RL, Lucas LM, Senfeld JI, Piazza JT, Neel LT, Whig K, Zhai L, Harris MH, Rael CC, Taylor DC, Cook LJ, Kaufmann DP, Mill CP, Jacobi MA, Smith FT, et al. Development and application of high-throughput screens for the discovery of compounds that disrupt ErbB4 signaling: Candidate cancer therapeutics. Plos One. 15: e0243901. PMID 33378376 DOI: 10.1371/journal.pone.0243901 |
0.756 |
|
| 2016 |
Kabir FM, DeInnocentes P, Agarwal P, Mill CP, Ii DJ, Bird RC. Estrogen receptor-α, progesterone receptor and c-erbB/HER-family receptor mRNA detection and phenotype analysis in spontaneous canine models of breast cancer. Journal of Veterinary Science. PMID 27515268 DOI: 10.4142/Jvs.2017.18.2.149 |
0.441 |
|
| 2015 |
Kanthala S, Mill CP, Riese DJ, Jaiswal M, Jois S. Expression And Purification Of HER2 Extracellular Domain Proteins In Schneider2 Insect Cells. Protein Expression and Purification. PMID 26363121 DOI: 10.1016/J.Pep.2015.09.001 |
0.697 |
|
| 2013 |
Gallo RM, Bryant IN, Mill CP, Kaverman S, Riese DJ. Multiple Functional Motifs Are Required for the Tumor Suppressor Activity of a Constitutively-Active ErbB4 Mutant. Journal of Cancer Research and Therapeutic Oncology. 1: 10. PMID 24791013 DOI: 10.17303/Jcrto.2013.1.104 |
0.772 |
|
| 2013 |
Nickerson NK, Mill CP, Wu HJ, Riese DJ, Foley J. Autocrine-derived epidermal growth factor receptor ligands contribute to recruitment of tumor-associated macrophage and growth of basal breast cancer cells in vivo. Oncology Research. 20: 303-17. PMID 23879171 DOI: 10.3727/096504013X13639794277761 |
0.719 |
|
| 2012 |
Wilson KJ, Mill C, Lambert S, Buchman J, Wilson TR, Hernandez-Gordillo V, Gallo RM, Ades LM, Settleman J, Riese DJ. EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling. Growth Factors (Chur, Switzerland). 30: 107-16. PMID 22260327 DOI: 10.3109/08977194.2011.649918 |
0.756 |
|
| 2012 |
Wilson KJ, Mill CP, Gallo RM, Cameron EM, VanBrocklin H, Settleman J, Riese DJ. The Q43L mutant of neuregulin 2β is a pan-ErbB receptor antagonist. The Biochemical Journal. 443: 133-44. PMID 22216880 DOI: 10.1042/Bj20110921 |
0.773 |
|
| 2011 |
Mill CP, Zordan MD, Rothenberg SM, Settleman J, Leary JF, Riese DJ. ErbB2 Is Necessary for ErbB4 Ligands to Stimulate Oncogenic Activities in Models of Human Breast Cancer. Genes & Cancer. 2: 792-804. PMID 22393464 DOI: 10.1177/1947601911431080 |
0.759 |
|
| 2011 |
Zordan MD, Mill CP, Riese DJ, Leary JF. A high throughput, interactive imaging, bright-field wound healing assay. Cytometry. Part a : the Journal of the International Society For Analytical Cytology. 79: 227-32. PMID 22045642 DOI: 10.1002/Cyto.A.21029 |
0.589 |
|
| 2011 |
Mill CP, Gettinger KL, Riese DJ. Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines. Experimental Cell Research. 317: 392-404. PMID 21110957 DOI: 10.1016/J.Yexcr.2010.11.007 |
0.746 |
|
| 2009 |
Mill CP, Chester JA, Riese DJ. EGFR may couple moderate alcohol consumption to increased breast cancer risk. Breast Cancer (Dove Medical Press). 1: 31-8. PMID 24367161 |
0.681 |
|
| 2007 |
Wilson KJ, Mill CP, Cameron EM, Hobbs SS, Hammer RP, Riese DJ. Inter-conversion of neuregulin2 full and partial agonists for ErbB4. Biochemical and Biophysical Research Communications. 364: 351-7. PMID 17945187 DOI: 10.1016/J.Bbrc.2007.10.004 |
0.707 |
|
| Show low-probability matches. |